Andrew Goldstein, an assistant professor of UCLA Molecular, Cell and Developmental Biology and Urology, as well as a faculty member of the UCLA IUO, will be honored by the American Cancer Society with its Giants of Science Hope award. Dr. Goldstein's research focuses on developing new treatments for prostate cancer.
The OLYMPUS Study - Optimized Delivery of Mitomycin for Primary UTUC Study
The purpose of this research study is to test the ability of UroGen’s MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. View Clinical Trial >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
UCLA researchers develop mechanism for characterizing function of rare tumor cells
UCLA researchers, including IUO's Dr. Matthew Rettig, have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive the disease of cancer. These findings could lead to more personalized treatments for people with cancer.